Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab

Annals of Hematology

Volumn 86, Issue 10, 2007, Pages 711-717

  Schweizer, Christof ^a   Reu, Frederic J ^a   Ho, Anthony D ^a   Hensel, Manfred ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Anti CD 20; Idiopathic thrombocytopenic purpura; ITP; Rituximab; Splenectomy

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; PREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ALLERGIC REACTION; ARTICLE; CHILL; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION COMPLICATION; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SPLENECTOMY; THROMBOCYTE COUNT;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PLATELET COUNT; PLATELET MEMBRANE GLYCOPROTEINS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SPLENECTOMY; TIME FACTORS;

EID: 34548363863     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-007-0335-1     Document Type: Article

References (51)

1. Ahmad HN, Ball C, Height SE, Rees DC (2004) Rituximab in chronic, recurrent HIV-associated immune thrombocytopenic purpura. Br J Haematol 127:607-608
2. Ahrens N, Kingreen D, Seltsam A, Salama A (2001) Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab). Br J Haematol 114:244-245
3. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG (2007) Systematic review: Efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 146:25-33
4. Bengtson KL, Skinner MA, Ware RE (2003) Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura. J Pediatr 143:670-673
5. Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC (2005) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 78:275-280
6. Bussel JB (2000) Overview of idiopathic thrombocytopenic purpura: New approach to refractory patients. Semin Oncol 27:91-98
7. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser JS, Wiznitzer I, Kelly R, Chen CF, Nichol JL (2006) AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 355:1672-1681
8. Carbone J, Escudero A, Mayayo M, Ballesteros M, Perez-Corral A, Sanchez-Ramon S, Sarmiento E, Micheloud D, Fernandez-Cruz E (2005) Partial response to anti-CD20 monoclonal antibody treatment of severe immune thrombocytopenic purpura in a patient with common variable immunodeficiency. Ann NY Acad Sci 1051:666-671
9. Choueiri T, Lichtin AE (2002) Hereditary hemorrhagic telangiectasia, idiopathic thrombocytopenic purpura, and chronic lymphocytic leukemia treated with rituximab. Am J Med 113:700-701
10. Cines DB, Blanchette VS (2002) Immune thrombocytopenic purpura. N Engl J Med 346:995-1008
11. Cines DB, McMillan R (2005) Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med 56:425-442
12. Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB (2004) The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 125:232-239
13. Cooper N, Stasi R, Michel M, Bussel JB (2003) Retreatment of 11 patients with immune thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab [abstract]. Blood 102(Suppl):87b
14. Fianchi L, Rossi E, Murri R, de Stefano V, Pagano L, Leone G (2007) Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura. Ann Hematol 86:225-226
15. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, Blanchette VS, Bussel JB, Cines DB, Kelton JG, Lichtin AE, McMillan R, Okerbloom JA, Regan DH, Warrier I (1996) Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood 88:3-40
16. Giagounidis AA, Anhuf J, Schneider P, Germing U, Sohngen D, Quabeck K, Aul C (2002) Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: A pilot study. Eur J Haematol 69:95-100
17. Grossi A, Santini V, Longo G, Balestri F, Ferrini P (2000) Treatment with anti CD 20 antibodies of patients with autoimmune thrombocytopenia with or without haemolytic anemia: Worsening in hemoglobin level [abstract]. Blood 96(Suppl):253a
18. Hegde UP, Wilson WH, White T, Cheson BD (2002) Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood 100:2260-2262
19. Hensel M, Ho AD (2003) Successful treatment of a patient with hairy cell leukemia and pentostatin-induced autoimmune thrombocytopenia with rituximab. Am J Hematol 73:37-40
20. Imbach P (2003) Refractory idiopathic immune thrombocytopenic purpura in children: Current and future treatment options. Paediatr Drugs 5:795-801
21. Introna M, Golay J, Barbui T (2003) Rituximab: A new therapeutic tool for primary immune thrombocytopenic purpura? Haematologica 88:482-484
22. Jacoub J, Mchlayeh W, Tabbara I, Dave HP, Siegel R, Schechter GP (2004) The use of anti-CD20 chimeric monoclonal antibody, rituximab in adult patients with treatment refractory immune thrombocytopenia [abstract]. Blood 104:74b
23. Koene HR (2006) Critical issues of current and future developments in the treatment of immune thrombocytopenic purpura. Pediatr Blood Cancer 47:703-705
24. Kojouri K, Vesely SK, Terrell DR, George JN (2004) Splenectomy for adult patients with idiopathic thrombocytopenic purpura: A systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 104:2623-2634
25. Lieb JV, Rossetti JM, Shadduck RK, Gryn JE, Kaplan RB, Zeigler ZR, Lister J (2003) Rituximab therapy for relapsed or refractory autoimmune thrombocytopenia [abstract]. Blood 102(Suppl):83b
26. Mantadakis E, Danilatou V, Stiakaki E, Kalmanti M (2004) Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases. Am J Hematol 77:303-310
27. McMillan R, Nugent D (2005) The effect of antiplatelet autoantibodies on megakaryocytopoiesis. Int J Hematol 81:94-99
28. Narang M, Penner JA, Williams D (2003) Refractory autoimmune thrombocytopenic purpura: Responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab). Am J Hematol 74:263-267
29. Narat S, Gandla J, Hoffbrand AV, Hughes RG, Mehta AB (2005) Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica 90:1273-1274
30. Papadakis KA, Rosenbloom B, Targan SR (2003) Anti-CD2O chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn's disease. Gastroenterology 124:583
31. Parodi E, Nobili B, Perrotta S, Rosaria Matarese SM, Russo G, Licciardello M, Zecca M, Locatelli F, Cesaro S, Bisogno G, Giordano P, De Mattia D, Ramenghia U (2006) Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: Efficacy and safety of treatment. Int J Hematol 84:48-53
32. Penalver FJ, Jimenez-Yuste V, Almagro M, Alvarez-Larran A, Rodriguez L, Casado M, Gallur L, Giraldo P, Hernandez R, Menor D, Rodriguez MJ, Caballero D, Gonzalez R, Mayans J, Millan I, Cabrera JR (2006) Rituximab in the management of chronic immune thrombocytopenic purpura: An effective and safe therapeutic alternative in refractory patients. Ann Hematol 85:400-406
33. Perrotta A, Abuel C (1998) Response of chronic relapsing ITP of 10 years duration to rituximab [abstract]. Blood 92(Suppl):88b
34. Perrotta A, Sunneberg TA, Scott J, Ratanatharaphorn V, Hook C, Attas L (1999) Rituxan in the treatment of chronic idiopathic thrombocytopenic purpura (ITP) [abstract]. Blood 94(Suppl):14a
35. Perrotta AL (2006) Re-treatment of chronic idiopathic thrombocytopenic purpura with rituximab: Literature review. Clin Appl Thromb Hemost 12:97-100
36. Price S, Cumpston A, Altaha R (2006) Use of rituximab in refractory autoimmune thrombocytopenia following an autologous stem cell transplant. Hematology 11:43-44
37. Raj K, Narayanan S, Augustson B, Ho A, Mehta P, Duncan N, Tauro S, Mahendra P, Craddock C, Mufti G (2005) Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation. Bone Marrow Transplant 35:299-301
38. Ratanatharathorn V, Carson E, Reynolds C, Ayash LJ, Levine J, Yanik G, Silver SM, Ferrara JL, Uberti JP (2000) Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 133:275-279
39. Robak T (2004) Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol 72:79-88
40. Russo G, Licciardello M, La Spina M (2004) Rituximab in children with idiopathic thrombocytopenic purpura: Does it really work? Eur J Pediatr 163:569
41. Sandler SG, Tutuncuoglu SO (2004) Immune thrombocytopenic purpura - current management practices. Expert Opin Pharmacother 5:2515-2527
42. Shvidel L, Klepfish A, Berrebi A (2001) Successful treatment with rituximab for relapsing immune thrombocytopenic purpura (ITP) associated with low-grade non-Hodgkin's lymphoma. Am J Hematol 67:213-214
43. Stasi R, Pagano A, Stipa E, Amadori S (2001) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98:952-957
44. Stasi R, Stipa E, Forte V, Meo P, Amadori S (2002) Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood 99:3872-3873
45. Stevens W, Koene H, Zwaginga JJ, Vreugdenhil G (2006) Chronic idiopathic thrombocytopenic purpura: Present strategy, guidelines and new insights. Neth J Med 64:356-363
46. Tamminga RY, Bruin MC (2006) Rituximab treatment for symptomatic chronic ITP. Pediatr Blood Cancer 47:714-716
47. Tomietto P, Gremese E, Tolusso B, Venturini P, De Vita S, Ferraccioli G (2004) B cell depletion may lead to normalization of anti-platelet, anti-erythrocyte and antiphospholipid antibodies in systemic lupus erythematosus. Thromb Haemost 92:1150-1153
48. Vesely SK, Perdue JJ, Rizvi MA, Terrell DR, George JN (2004) Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: A systematic review. Ann Intern Med 140:112-120
49. Zaja F, Vianelli N, Battista M, Sperotto A, Patriarca F, Tomadini V, Fili C, Tani M, Baccarani M, Fanin R (2006) Earlier administration of rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. Exp Hematol 34:571-572
50. Zaja F, Vianelli N, Sperotto A, De Vita S, Iacona I, Zaccaria A, Masolini P, Tomadini V, Tani M, Molinari AL, Baccarani M, Fanin R (2003) B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 88:538-546
51. Zaja F, Vianelli N, Sperotto A, Patriarca F, Tani M, Marin L, Tiribelli M, Candoni A, Baccarani M, Fanin R (2003) Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma 44:1951-1955